Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

Detalles Bibliográficos
Autor principal: Lieberman, Howard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798247/
https://www.ncbi.nlm.nih.gov/pubmed/35117386
http://dx.doi.org/10.21037/tcr.2019.12.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798247/
https://www.ncbi.nlm.nih.gov/pubmed/35117386
http://dx.doi.org/10.21037/tcr.2019.12.102

Ejemplares similares